Vodafone and Kaltura Sign a Long-Term Partnership Agreement to Expand Cloud TV Services

Already partners for over 10 years, the now extended partnership further strengthens Vodafone’s Cloud TV market leadership across Europe throughout the next decade

New York, Aug. 04, 2025 (GLOBE NEWSWIRE) —

Vodafone Group PLC (Nasdaq: VOD) and Kaltura (Nasdaq: KLTR), the AI Video Experience Cloud, today announced that they have extended their partnership around the Kaltura-powered Vodafone TV solution (VTV). 

Vodafone launched VTV in 2014, and it has since grown to serve several million subscribers across eight markets, consistently delivering reliable, high-quality video experiences to viewers. 

Kaltura’s platform has been supporting Vodafone’s continued transition from providing traditional on-premises based IPTV services to offering cloud-native over-the-top services. The partnership has driven innovation and growth for both companies and has enabled the rapid rollout and continuous evolution of Cloud TV services. 

Under the extended partnership, Kaltura and Vodafone plan to evolve the current solution in capabilities and functionalities and expand it to more subscribers, and potentially to additional markets. The partnership will also explore the deployment of new AI-infused Kaltura products that further boost user engagement, interactivity, and personalization, and that increase monetization and operational efficiency.  

The partnership extension reaffirms the depth and breadth of collaboration between the two companies, and the robustness, and scalability of VTV and of Kaltura’s platform.   

“We partnered with Kaltura over ten years ago due to its innovative vision, and together we’ve built, and deployed to millions of subscribers across multiple countries, a market leading Cloud TV platform that combines the best of OTT and Pay-TV into a scalable service,” said Alberto Ripepi, Group Chief Network Officer at Vodafone. “We have a strong partnership with Kaltura, and look forward to continuing our joint innovation, leadership, and growth for many more years.” 

“It has been a great privilege and honor to partner with Vodafone over the last decade and bring to market together the worlds’ leading cloud TV service,” said Ron Yekutiel, Co-founder, Chairman, President, and CEO of Kaltura. “We are very excited to extend and deepen our partnership, as well as about the prospect of deploying new AI-infused offerings that would supercharge customer engagement, interactivity, and personalization, and boost monetization and operational efficiency.” 

About Vodafone 

Vodafone is a leading European and African telecoms company.  We serve over 340 million mobile and broadband customers, operating networks in 15 countries with investments in a further five and partners in over 40 more. Our undersea cables transport around a sixth of the world’s internet traffic, and we are developing a new direct-to-mobile satellite communications service to connect areas without coverage. Vodafone runs one of the world’s largest IoT platforms, with 205 million IoT connections, and we provide financial services to around 88 million customers across seven African countries – managing more transactions than any other provider. From the seabed to the stars, Vodafone’s purpose is to keep everyone connected. 

About Kaltura 

Kaltura’s mission is to create and power AI-infused hyper-personalized video experiences that boost customer and employee engagement and success. Kaltura’s Video Experience Cloud includes a platform for enterprise and TV content management and a wide array of Gen AI-infused video-first products, including Video Portals, LMS and CMS Video Extensions, Virtual Events and Webinars, Virtual Classrooms, and TV Streaming Applications. Kaltura engages millions of end-users at home, at work, and at school, boosting both customer and employee experiences, including marketing, sales, and customer success; teaching, learning, training and certification; communication and collaboration; and entertainment and monetization. For more information, visit  www.corp.kaltura.com  



Kaltura 

Nohar Zmora 

SVP, Head of Marketing 

[email protected] 

 

Vodafone 

Media Relations: 
Vodafone.com/media/contact 
[email protected] 

Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).

Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=159243&from=3

CLASS PERIOD: September 17, 2024 to May 26, 2025

ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501’s safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial’s protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket’s securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made “several months” earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket’s common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket’s stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.

DEADLINE: August 11, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=159243&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RCKT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 11, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903



Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 130,000 shares of the Company’s common stock, effective as of August 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $5.33 per share, equal to the last reported sale price of the Company’s common stock as reported by Nasdaq on August 1, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact

Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]



Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America.

Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. Knight and Incyte had entered into an exclusive supply and distribution agreement for MINVUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) in Latin America in September 2021.

Retifanlimab is approved in the United States and Europe for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1 Based on epidemiological data from two Brazilian registries, there are an estimated 550 – 1,250 new cases of MCC each year across Brazil, Mexico, Colombia and Argentina.2 Retifanlimab is also approved by the U.S. Food and Drug Administration (FDA) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).1 In addition, the FDA approved retifanlimab as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.1 While epidemiological data for SCAC in LATAM is limited, there are approximately 2,700 – 4,000 new cases of SCAC each year in Brazil, Mexico, Colombia and Argentina.3

Axatilimab received FDA approval in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.4 Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor’s immune cells attack the recipient’s tissues, potentially affecting multiple organs such as the skin, liver, lungs, and gastrointestinal tract. There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.5

“We are thrilled to expand our partnership with Incyte and for the opportunity to bring two innovative biologic products to the LATAM region,” said Samira Sakhia, President and CEO of Knight Therapeutics. “These therapies are highly complementary to our existing portfolio and will significantly strengthen our presence in oncology and hematology, reinforcing our commitment to delivering transformative treatments to patients across Latin America.”

“As a partner, Knight, has an extensive track record of successful collaborations as well as strong distribution capabilities in Latin America,” said Lee Heeson, Executive Vice President and Head of Incyte International. “We look forward to continuing to work together and to expanding our existing partnership for tafasitamab and pemigatinib to include retifanlimab and axatilimab so that eligible patients in the region can access our innovative medicines.”

About Retifanlimab

ZYNYZ® (retifanlimab-dlwr) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S.1

ZYNYZ® is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1

ZYNYZ® is marketed by Incyte in the United States. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

ZYNYZ® is a registered trademark of Incyte.

About Axatilimab

NIKTIMVO™ (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg .4

In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in cGVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD; a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids which are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

NIKTIMVO™ is a trademark of Incyte. All other trademarks are the property of their respective owners.

References

  1. Incyte Corporation. ZYNYZ (retifanlimab-dlwr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from
    https://www.zynyz.com/zynyz-prescribing-information.
  2. Melo, Andreia C de, and Luiz C Santos Thuler. “Trends in the Incidence and Morbidity of Merkel Cell Carcinoma in Brazil.” Future Oncology 17, no. 22 (May 7, 2021): 2857–65. https://doi.org/10.2217/fon-2020-1313.
  3. Mignozzi, Silvia, Claudia Santucci, Matteo Malvezzi, Fabio Levi, Carlo La Vecchia, and Eva Negri. “Global Trends in Anal Cancer Incidence and Mortality.” European Journal of Cancer Prevention 33, no. 2 (November 27, 2023): 77–86. https://doi.org/10.1097/cej.0000000000000842.
  4. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf.
  5. Associação Brasileira De Transplante De Órgãos. “Registro Brasileiro de Transplantes.”XXV No. 3. https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2024, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:  
Knight Therapeutics Inc.  
   
Samira Sakhia Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116  
Email: [email protected] Email: [email protected]
Website: www.knighttx.com Website: www.knighttx.com



Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET

HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Investor Inquiries:

(508) 893-3120
[email protected]



Unitil Reports Second Quarter Earnings

HAMPTON, N.H., Aug. 04, 2025 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE: UTL) (unitil.com) today announced Net Income of $4.0 million, or $0.25 in Earnings Per Share (EPS) for the second quarter of 2025, a decrease of $0.3 million in Net Income, or $0.02 in EPS, compared to the second quarter of 2024. For the six months ended June 30, 2025, the Company reported Net Income of $31.5 million, or $1.94 in EPS. Net income is unchanged and EPS decreased $0.02 when compared to the first six months of 2024. The Company’s Adjusted Net Income (a non-GAAP financial measure1), which excluded transaction-related costs in connection with the acquisition of Bangor Natural Gas Company (Bangor), Maine Natural Gas Company (Maine Natural) and Aquarion Water Company of Massachusetts, Inc., Aquarion Water Company of New Hampshire, Inc., and Abenaki Water Co., Inc. (the Aquarion Companies), was $4.7 million, or $0.29 in EPS, for the second quarter of 2025, an increase of $0.4 million, or $0.02 in EPS, compared to the second quarter of 2024. For the six months ended June 30, 2025, the Company’s Adjusted Net Income, which excluded transaction-related costs in connection with the acquisition of Bangor, Maine Natural and the Aquarion Companies, was $33.1 million, or $2.03 in EPS, an increase of $1.6 million, or $0.07 in EPS compared to the first six months of 2024.

“Unitil once again delivered strong financial results reflecting our focus on operational excellence and strong customer service,” said Thomas P. Meissner, Jr., Unitil’s Chairman and Chief Executive Officer. “We continue to execute on all elements of our long-term strategy, even as we capitalize on opportunistic utility acquisitions. Our regulatory initiatives, financial discipline, and best-in-class customer service will continue to drive long-term sustainable value for all stakeholders.”

Electric GAAP Gross Margin was $18.0 million in the three months ended June 30, 2025, an increase of $0.2 million compared to the same period in 2024. Electric GAAP Gross Margin was $37.6 million in the six months ended June 30, 2025, a decrease of $0.3 million compared to the same period in 2024. The three month period increase was driven by higher rates and customer growth of $0.9 million, partially offset by higher depreciation and amortization expense of $0.7 million. The six month period decrease was driven by higher depreciation and amortization expense of $1.6 million, partially offset by higher rates and customer growth of $1.3 million.

________________________
1 The accompanying Supplemental Information more fully describes the non-GAAP financial measures used in this press release and includes a reconciliation of the non-GAAP financial measures to the financial measures that the Company’s management believes are the most comparable GAAP financial measures. The Supplemental Information also includes a discussion of the changes in the most comparable GAAP financial measures for the periods presented.
________________________

Electric Adjusted Gross Margin (a non-GAAP financial measure1) was $25.8 million and $53.3 million in the three and six months ended June 30, 2025, respectively, increases of $0.9 million and $1.3 million, respectively, compared to the same periods in 2024. These increases reflect higher rates and customer growth.

Gas GAAP Gross Margin was $23.2 million in the three months ended June 30, 2025, an increase of $2.7 million compared to the same period in 2024. Gas GAAP Gross Margin was $80.3 million in the six months ended June 30, 2025, an increase of $9.7 million compared to the same period in 2024. The increase in the three month period was driven by higher rates and customer growth of $5.9 million, partially offset by higher depreciation and amortization of $3.2 million. The increase in the six month period was driven by higher rates and customer growth of $13.8 million, the favorable effects of colder winter weather in 2025 of $2.0 million, partially offset by higher depreciation and amortization of $6.1 million. Included in gas operating revenue, cost of gas sales and depreciation and amortization for the three months ended June 30, 2025 is $4.7 million, $1.7 million and $0.7 million related to Bangor, respectively. Included in gas operating revenue, cost of gas sales and depreciation and amortization for the six months ended June 30, 2025 is $13.3 million, $7.4 million and $1.3 million related to Bangor, respectively.

Gas Adjusted Gross Margin (a non-GAAP financial measure1) was $37.2 million and $108.1 million in the three and six months ended June 30, 2025, respectively, increases of $5.9 million and $15.8 million, respectively, compared to the same periods in 2024. The increase in the three month period reflects higher rates and customer growth of $5.9 million. The increase in the six month period reflects higher rates and customer growth of $13.8 million and the favorable effects of colder winter weather of $2.0 million in 2025. Included in the Gas Adjusted Gross Margin for the three and six months ended June 30, 2025 is $3.0 million and $5.9 million, respectively, related to Bangor.

Operation and Maintenance (O&M) expenses increased $2.7 million and $7.1 million in the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024. The increase in the three month period reflects higher utility operating costs of $1.5 million, higher labor costs of $0.6 million and higher professional fees of $0.6 million. The increase in the six month period reflects higher utility operating costs of $3.1 million, higher labor costs of $2.1 million and higher professional fees of $1.9 million. Included in O&M expense for the three months and six months ended June 30, 2025 is $0.8 million and $1.7 million, respectively, related to Bangor O&M expenses and $1.0 million and $2.2 million, respectively, in acquisition transaction costs.

Depreciation and Amortization expense increased $3.7 million and $7.4 million in the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024, reflecting higher depreciation rates from recent base rate cases, additional depreciation associated with higher levels of utility plant in service and higher amortization of recoverable storm costs and other deferred costs. Included in Depreciation and Amortization for the three months and six months ended June 30, 2025 is $0.7 million and $1.3 million, respectively, related to Bangor.

Taxes Other Than Income Taxes decreased $0.5 million and $0.3 million in the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024, primarily due to lower excise taxes.

Other Expense (Income), Net decreased $0.8 million and $1.0 million in the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024, reflecting lower retirement benefit costs.

Interest Expense, Net increased $1.9 million and $3.7 million in the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024, primarily reflecting higher levels of long-term debt, higher interest expense on regulatory liabilities and lower interest income on AFUDC and other, partially offset by lower interest expense on short-term borrowings.

Provision for Income Taxes increased $0.1 million and $0.2 million in the three and six months ended June 30, 2025, respectively, compared with the same periods in 2024. The increase in the six month period reflects higher pre-tax earnings in 2025.

At its January 2025, May 2025 and July 2025 meetings, the Unitil Corporation Board of Directors declared quarterly dividends on the Company’s common stock of $0.45 per share. These quarterly dividends result in a current effective annualized dividend rate of $1.80 per share, representing an unbroken record of quarterly dividend payments since trading began in Unitil’s common stock.

The Company’s earnings are seasonal and are typically higher in the first and fourth quarters when customers use natural gas for heating purposes.

The Company will hold a quarterly conference call to discuss second quarter 2025 results on Tuesday, August 5, 2025, at 2:00 p.m. Eastern Time. This call is being webcast. This call, financial and other statistical information contained in the Company’s presentation on this call, and information required by Regulation G regarding non-GAAP financial measures can be accessed in the Investor Relations section of Unitil’s website, unitil.com.

About Unitil Corporation

Unitil Corporation provides energy for life by safely and reliably delivering electricity and natural gas in New England. We are committed to the communities we serve and to developing people, business practices, and technologies that lead to the delivery of dependable, more efficient energy. Unitil Corporation is a public utility holding company with operations in Maine, New Hampshire and Massachusetts. Together, Unitil’s operating utilities serve approximately 109,400 electric customers and 97,600 natural gas customers. For more information about our people, technologies, and community involvement please visit unitil.com.

Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical fact, included in this press release are forward-looking statements. Forward-looking statements include declarations regarding Unitil’s beliefs and current expectations. These forward-looking statements are subject to the inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. Some, but not all, of the risks and uncertainties include the following: Unitil’s regulatory environment (including regulations relating to climate change, greenhouse gas emissions and other environmental matters); fluctuations in the supply of, the demand for, and the prices of, energy commodities and transmission and transportation capacity and Unitil’s ability to recover energy commodity costs in its rates; customers’ preferred energy sources; severe storms and Unitil’s ability to recover storm costs in its rates; general economic conditions; variations in weather; long-term global climate change; unforeseen or changing circumstances, which could adversely affect the reduction of company-wide direct greenhouse gas emissions; Unitil’s ability to retain its existing customers and attract new customers; increased competition; and other risks detailed in Unitil’s filings with the Securities and Exchange Commission. These forward looking statements speak only as of the date they are made. Unitil undertakes no obligation, and does not intend, to update these forward-looking statements except as required by law.

For more information please contact:         

Christopher Goulding – Investor Relations   Amanda Vicinanzo – External Affairs
Phone: 603-773-6466   Phone: 603-691-7784
     
Email: [email protected]   Email: [email protected]



Supplemental Information; Non-GAAP Financial Measures

The Company’s earnings discussion includes Adjusted Net Income, a non-GAAP financial measure referencing the Company’s 2025 GAAP Net Income adjusted for certain transaction costs related to the Company’s acquisition of Bangor, which it disclosed previously in 2024, and the Company’s acquisitions of Maine Natural and the Aquarion Companies. The Company’s management believes that the transaction costs related to the acquisitions of Bangor, Maine Natural, and the Aquarion Companies, which are included in Operation and Maintenance expense on the Consolidated Statements of Earnings, are not indicative of the Company’s ongoing costs and not directly related to the ongoing operations of the business and therefore are not an indicator of baseline operating performance.

In the following tables the Company has reconciled Adjusted Net Income to GAAP Net Income, which we believe to be the most comparable GAAP financial measure.

(Millions, except per share data)                        
    Three Months Ended June 30, 2025     Three Months Ended June 30, 2024  
    Amount     Per Share     Amount     Per Share  
GAAP Net Income   $ 4.0     $ 0.25     $ 4.3     $ 0.27  
Transaction Costs     0.7       0.04              
Adjusted Net Income   $ 4.7     $ 0.29     $ 4.3     $ 0.27  
                         
                         
    Six Months Ended June 30, 2025     Six Months Ended June 30, 2024  
    Amount     Per Share     Amount     Per Share  
GAAP Net Income   $ 31.5     $ 1.94     $ 31.5     $ 1.96  
Transaction Costs     1.6       0.09              
Adjusted Net Income   $ 33.1     $ 2.03     $ 31.5     $ 1.96  


The Company analyzes operating results using Electric and Gas Adjusted Gross Margins, which are non-GAAP financial measures. Electric Adjusted Gross Margin is calculated as Total Electric Operating Revenue less Cost of Electric Sales. Gas Adjusted Gross Margin is calculated as Total Gas Operating Revenues less Cost of Gas Sales. The Company’s management believes Electric and Gas Adjusted Gross Margins provide useful information to investors regarding profitability. Also, the Company’s management believes Electric and Gas Adjusted Gross Margins are important financial measures to analyze revenue from the Company’s ongoing operations because the approved cost of electric and gas sales are tracked, reconciled and passed through directly to customers in electric and gas tariff rates, resulting in an equal and offsetting amount reflected in Total Electric and Gas Operating Revenue.

In the following tables the Company has reconciled Electric and Gas Adjusted Gross Margin to GAAP Gross Margin, which we believe to be the most comparable GAAP financial measure. GAAP Gross Margin is calculated as Revenue less Cost of Sales and Depreciation and Amortization. The Company calculates Electric and Gas Adjusted Gross Margin as Revenue less Cost of Sales. The Company believes excluding Depreciation and Amortization, which are period costs and not related to volumetric sales, is a meaningful measure to inform investors of the Company’s profitability from electric and gas sales in the period.

Three Months Ended June 30, 2025 (millions)  
    Electric     Gas     Other     Total  
Total Operating Revenue   $ 51.0     $ 51.6     $     $ 102.6  
Less: Cost of Sales     (25.2 )     (14.4 )           (39.6 )
Less: Depreciation and Amortization     (7.8 )     (14.0 )           (21.8 )
GAAP Gross Margin     18.0       23.2             41.2  
Depreciation and Amortization     7.8       14.0             21.8  
Adjusted Gross Margin   $ 25.8     $ 37.2     $     $ 63.0  

Three Months Ended June 30, 2024 (millions)  
    Electric     Gas     Other     Total  
Total Operating Revenue   $ 56.4     $ 39.3     $     $ 95.7  
Less: Cost of Sales     (31.5 )     (8.0 )           (39.5 )
Less: Depreciation and Amortization     (7.1 )     (10.8 )     (0.2 )     (18.1 )
GAAP Gross Margin     17.8       20.5       (0.2 )     38.1  
Depreciation and Amortization     7.1       10.8       0.2       18.1  
Adjusted Gross Margin   $ 24.9     $ 31.3     $     $ 56.2  

Six Months Ended June 30, 2025 (millions)  
    Electric     Gas     Other     Total  
Total Operating Revenue   $ 111.2     $ 162.2     $     $ 273.4  
Less: Cost of Sales     (57.9 )     (54.1 )           (112.0 )
Less: Depreciation and Amortization     (15.7 )     (27.8 )           (43.5 )
GAAP Gross Margin     37.6       80.3             117.9  
Depreciation and Amortization     15.7       27.8             43.5  
Adjusted Gross Margin   $ 53.3     $ 108.1     $     $ 161.4  

Six Months Ended June 30, 2024 (millions)  
    Electric     Gas     Other     Total  
Total Operating Revenue   $ 130.0     $ 144.4     $     $ 274.4  
Less: Cost of Sales     (78.0 )     (52.1 )           (130.1 )
Less: Depreciation and Amortization     (14.1 )     (21.7 )     (0.3 )     (36.1 )
GAAP Gross Margin     37.9       70.6       (0.3 )     108.2  
Depreciation and Amortization     14.1       21.7       0.3       36.1  
Adjusted Gross Margin   $ 52.0     $ 92.3     $     $ 144.3  

Selected financial data for 2025 and 2024 is presented in the following table:

Unitil Corporation – Condensed Consolidated Financial Data
(Millions, except Per Share data) (Unaudited)
             
    Three Months Ended June 30,   Six Months Ended June 30,
    2025   2024   Change   2025   2024   Change
Electric kWh Sales:                                    
Residential     138.9       140.8       -1.3 %     338.7       320.7       5.6 %
Commercial/Industrial     207.7       221.8       -6.4 %     446.1       451.8       -1.3 %
Total Electric kWh Sales     346.6       362.6       -4.4 %     784.8       772.5       1.6 %
Gas Therm Sales:                                    
Residential     10.4       8.6       20.9 %     38.7       29.8       29.9 %
Commercial/Industrial     45.0       37.9       18.7 %     129.8       106.4       22.0 %
Total Gas Therm Sales     55.4       46.5       19.1 %     168.5       136.2       23.7 %
                                     
                                     
Electric Revenues   $ 51.0     $ 56.4     $ (5.4 )   $ 111.2     $ 130.0     $ (18.8 )
Cost of Electric Sales     25.2       31.5       (6.3 )     57.9       78.0       (20.1 )
Electric Adjusted Gross Margin                                    
(a non-GAAP financial measure

1

):
    25.8       24.9       0.9       53.3       52.0       1.3  
Gas Revenues     51.6       39.3       12.3       162.2       144.4       17.8  
Cost of Gas Sales     14.4       8.0       6.4       54.1       52.1       2.0  
Gas Adjusted Gross Margin                                    
(a non-GAAP financial measure

1

):
    37.2       31.3       5.9       108.1       92.3       15.8  
Total Adjusted Gross Margin:                                    
(a non-GAAP financial measure

1

):
    63.0       56.2       6.8       161.4       144.3       17.1  
Operation & Maintenance Expenses     21.3       18.6       2.7       43.9       36.8       7.1  
Depreciation & Amortization     21.8       18.1       3.7       43.5       36.1       7.4  
Taxes Other Than Income Taxes     6.6       7.1       (0.5 )     14.5       14.8       (0.3 )
Other Expense (Income), Net     (0.7 )     0.1       (0.8 )     (0.6 )     0.4       (1.0 )
Interest Expense, Net     9.3       7.4       1.9       18.4       14.7       3.7  
Income Before Income Taxes     4.7       4.9       (0.2 )     41.7       41.5       0.2  
Provision for Income Taxes     0.7       0.6       0.1       10.2       10.0       0.2  
Net Income   $ 4.0     $ 4.3     $ (0.3 )   $ 31.5     $ 31.5     $  
Earnings Per Share   $ 0.25     $ 0.27     $ (0.02 )   $ 1.94     $ 1.96     $ (0.02 )



Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.

The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Investor Contact:

Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]

Media Contact:

EvolveMKD
646-517-4220
[email protected]



LM Funding America Announces Second Quarter 2025 Earnings Call for August 14, 2025

TAMPA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today announced that it has scheduled its second quarter 2025 earnings conference call and webcast for Thursday, August 14, 2025 at 8:00 AM EST.

LM Funding will publish its second quarter 2025 results as well as an accompanying investor presentation the morning of August 14, 2025 before the call. A copy of the earnings release and investor presentation will be available on the Company’s Investor Relations website at https://www.lmfunding.com/investors.

Conference Call Details:

  • Date: August 14, 2025
  • Time: 8:00 AM EST
  • Participant Call Links:
    • Live Webcast: Link
    • Participant Call Registration: Link

About LM Funding America

LM Funding America, Inc. (Nasdaq: LMFA), operates as a Bitcoin mining and specialty finance company. The company was founded in 2008 and is based in Tampa, Florida. For more information, please visit https://www.lmfunding.com.

For investor and media inquiries, please contact:

Investor Relations

Orange Group
Yujia Zhai
[email protected]



Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

  • Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented

     
  • End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025

     
  • Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025

     
  • eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025

     
  • AstraZeneca partnership: R&D activities are continuing to advance for the three programs initiated

     
  • Appointment of Mr. André Muller as Director to Cellectis’ Board of Directors

     
  • Cash, cash equivalents and fixed-term deposits of
    $230 million as of June 30, 2025
    1
    provides runway into H2 2027

     
  • Conference call and webcast scheduled for tomorrow, August 5, 2025 at 8:00AM ET / 2:00PM CET

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the second quarter 2025 ending June 30, 2025 and business updates.

“I am pleased to announce that Cellectis will host an Investor R&D Day in New York City on October 16, 2025. The Company’s leadership team and key opinion leaders will present the Phase 1 dataset and outline the late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL and will share insights on the Company’s vision and differentiated capabilities,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis.

“Our teams have remained focused on advancing research and developing solutions for patients with unmet medical needs. In July 2025, we completed the end-of-Phase 1 multidisciplinary meetings with both the FDA and EMA for lasme-cel in r/r B-ALL. We are excited about a pivotal Phase 2 which we expect to initiate in the second half of this year.”

Pipeline Highlights

UCART Clinical Programs

BALLI-01 study evaluating lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

  • In July 2025, Cellectis completed the multidisciplinary end-of-Phase 1 regulatory interactions with both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Preparations are currently underway in anticipation for an amendment to initiate a pivotal Phase 2 of lasme-cel in r/r B-ALL, which is expected in H2 2025.
  • Cellectis will present the Phase 1 dataset and late-stage development strategy for lasme-cel in r/r B-ALL at an Investor R&D Day that will take place on October 16, 2025 in New York City.

NatHaLi-01 study evaluating eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL)

  • Cellectis continues to focus on the enrollment of patients in the NatHaLi-01 study and expects to present a Phase 1 readout for eti-cel in r/r NHL in late 2025.

Partnerships

Servier – Anti-CD19 CAR-T

  • In May 2025, Allogene Therapeutics, Inc. (“Allogene”), Servier’ sublicensee, announced that, as part of the ALPHA3 clinical trial evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, the milestone for lymphodepletion regimen selection and futility analysis has been shifted by approximately two quarters and is now expected by Allogene in the first half of 2026.
  • On August 1, 2025, Allogene announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study. The arm testing FC plus ALLO-647, an anti-CD52 mAb (FCA), is now closed to further enrollment. According to Allogene, this decision, made ahead of the scheduled futility analysis, was prompted by a Grade 5 adverse event in the FC plus ALLO-647 arm that has been attributed to the use of ALLO-647. According to Allogene, this event was deemed unrelated to cema-cel. Allogene further announced that the amended ALPHA3 trial now proceeds as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation, the current standard of care. Statistical design of the trial and the prespecified study conduct remain the same. The next milestone will be the futility analysis comparing MRD conversion and is expected by Allogene to occur 1H 2026.

Allogene – Anti-CD70 CAR-T

  • In June 2025, Allogene presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma during an oral presentation at the 2025 ASCO Annual Meeting. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine following by a single dose of 80 million CAR-T cells.

AstraZeneca – Joint Research and Collaboration Agreement

  • Research and development activities are continuing to advance for the three cell and gene therapy programs under our Joint Research and Collaboration Agreement with AstraZeneca in November 2023 (the “AZ JRCA”): one allogeneic CAR-T for hematological malignancies, one allogeneic CAR-T for solid tumors, and one in vivo gene therapy for a genetic disorder.

Servier arbitration

  • With respect to the ongoing arbitration proceeding through the Centre de Médiation et d’Arbitrage de Paris, the arbitral decision is expected to be rendered on or before December 15, 2025.

Corporate Updates

Annual Shareholders’ Meeting

  • On June 26, 2025, Cellectis held a Shareholders General Meeting at the Biopark auditorium in Paris, France. At the meeting, during which approximately 57% of voting rights were exercised, resolutions 1 through 23 and resolutions 25 and 26 were adopted, while resolution 24 was rejected, consistent with the recommendations of the Board of Directors. The detailed results of the vote and the resolutions are available on Cellectis’ website: https://www.cellectis.com/en/investors/general-meetings/
  • The Cellectis Shareholders’ Meeting appointed Mr. André Muller as a director of the Company’s Board of Directors, with immediate effect. In addition, at the close of this meeting, the term of Mr. Axel-Sven Malkomes expired, and the previously announced resignation of Mr. Pierre Bastid became effective. In connection with these changes to the Board of Directors, the Board of Directors appointed André Muller, Donald Bergstrom, and Rainer Boehm as the members of the Company’s Audit Committee.

Financial Results 

Cash, cash equivalent and fixed-term deposits: As of June 30, 2025, Cellectis had $230 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current and non-current financial assets. The Company believes its cash, cash equivalents and fixed-term deposits will be sufficient to fund its operations into H2 2027.

This compares to $264 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current financial assets as of December 31, 2024, with no fixed-term deposits classified as non-current financial assets as of such date. This $33.2 million change includes $13.4 million of cash-in from our revenue, $5.1 million of interest income from our financial and cash-equivalent investments, offset by cash payments from Cellectis to suppliers of $23.2 million, Cellectis’ wages, bonuses and social expenses paid of $23.6 million, the payments of lease debts of $5.4 million, the repayment of the “PGE” loan of $2.6 million and the payments of capital expenditures for $0.7 million.

We currently foresee focusing our cash spending in supporting the development of our pipeline of product candidates, including the manufacturing and clinical trial expenses of lasme-cel (UCART22), eti-cel (UCART20x22) and potential new product candidates, and operating our state-of-the-art manufacturing capabilities in Paris (France) and Raleigh (North Carolina).

Revenues and Other Income: Consolidated revenues and other income were $30.2 million for the six-month period ended June 30, 2025, compared to $16.0 million for the six-month period ended June 30, 2024. This $14.2 million increase between the six-month period ended June 30, 2024 and 2025 was mainly attributable to a $20.0 million increase in revenue recognized under AstraZeneca Joint Research Collaboration Agreement in the first half 2025 based on the progress of our performance obligation rendered under the three research programs, partly offset by a slight decrease in other income by $0.6 million and by a one-off development milestone revenue of $5.4 million recorded last year as of June 30, 2024 under the Servier License Agreement.

R&D Expenses: Consolidated R&D expenses were $45.0 million for the six-month period ended June 30, 2025, compared to $45.8 million for the six-month period ended June 30, 2024, down by $0.8 million mainly driven by a decrease in purchases & external expenses and other expenses of $1.7 million, offset by an increase of $0.7 million in depreciation & amortization expenses and by a slight increase of $0.2 million in R&D personnel expenses related to non-cash stock based compensation.

SG&A Expenses: Consolidated SG&A expenses were $9.8 million for the six-month period ended June 30, 2025, compared to $9.0 million for the six-month period ended June 30, 2024. The $0.8 million change is mainly due to a non-cash stock-based compensation increase of $0.3 million and an increase of $0.6 million in purchases and external expenses, partially offset for by a decrease in amortization expenses of $0.1 million.

Other operating income and expenses: Other operating income increased slightly by $0.1 million between the six-month periods ended June 30, 2024, and 2025.

Net financial gain (loss): We had a consolidated net financial loss of $18.1 million for the six-month period ended June 30, 2025, compared to an $18.0 million net financial gain for the six-month period ended June 30, 2024. This $36.1 million difference reflects mainly (i) a one-off $14.3 million gain in change in fair value of the derivative instrument component of the Subsequent Investment Agreement dated November 7, 2023 between us and AstraZeneca Holdings (the “SIA”), which was recognized in the six-month period ended June 30, 2024, (ii) a $3.5 million decrease in change in fair value of the warrants issued to the European Investment Bank (“EIB”), as required by our finance contract entered into with EIB in December 2022, (iii) a $22.5 million increase in foreign exchange loss and a $1.0 million decrease in foreign exchange gain over the period due to the USD devaluation and (iv) a $0.3 million increase in interests on financial and lease liabilities, partially offset by (v) a $0.4 million increase in income from our financial investments and cash-equivalents, (vi) a $4.5 million decrease in loss on fair value mainly due to our investment in shares of Cibus, Inc., which was entirely sold in the first quarter of 2025 and (vii) a $0.6 million gain in fair value of foreign exchange derivatives recorded during the period.

Net Income (loss) Attributable to Shareholders of Cellectis: Consolidated net loss attributable to shareholders of Cellectis was $41.9 million (or a $0.42 net loss per share) for the six-month period ended June 30, 2025, compared to a $19.6 million net loss (or a $0.24 net loss per share) for the six-month period ended June 30, 2024. The $22.2 million change in net loss was primarily driven by (i) an increase in revenues and other income of $14.2 million and (ii) a $0.1 million decrease in operating expenses and other operating income, offset by (iii) a $36.1 million change from a net financial gain of $18.0 million as of June 30, 2024 to a net financial loss of $18.1 million as of June 30, 2025 and (iv) a decrease in deferred tax asset income of $0.5 million.

Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: Consolidated adjusted net loss attributable to shareholders of Cellectis was $39.6 million (or a $0.40 loss per share) for the six-month period ended June 30, 2025, compared to a net loss of $17.9 million (or a $0.22 loss per share) for the six-month period ended June 30, 2024.

The interim condensed consolidated financial statements of Cellectis have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).

Please see “Note Regarding Use of Non-IFRS Financial Measures” for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis.

CELLECTIS S.A.

INTERIM CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited)

($ in thousands)
 
    As of
    December 31, 2024   June 30, 2025
ASSETS         
Non-current assets         
Intangible assets   1,116     1,153  
Property, plant, and equipment   45,895     42,790  
Right-of-use assets   29,968     27,383  
Non-current financial assets   7,521     35,491  
Other non-current assets   11,594     16,127  
Deferred tax assets   382     382  
Total non-current assets    96,476     123,326  
Current assets         
Trade receivables   6,714     8,776  
Subsidies receivables   14,521     16,382  
Other current assets   5,528     7,333  
Cash and cash equivalent and Current financial assets   260,306     198,151  
Total current assets    287,069     230,641  
TOTAL ASSETS    383,544     353,966  
LIABILITIES         
Shareholders’ equity         
Share capital   5,889     5,902  
Premiums related to the share capital   494,288     433,549  
Currency translation adjustment   (39,537 )   (33,885 )
Retained earnings   (292,846 )   (266,592 )
Net income (loss)   (36,761 )   (41,863 )
Total shareholders’ equity – Group Share   131,033     97,111  
Non-controlling interests        
Total shareholders’ equity   131,033     97,111  
Non-current liabilities         
Non-current financial liabilities   50,882     55,856  
Non-current lease debts   34,245     32,264  
Non-current provisions   1,115     1,303  
Total non-current liabilities    86,241     89,424  
Current liabilities         
Current financial liabilities   16,134     18,230  
Current lease debts   8,385     7,477  
Trade payables   18,664     17,522  
Deferred revenues and deferred income   112,161     113,379  
Current provisions   828     875  
Other current liabilities   10,097     9,949  
Total current liabilities    166,269     167,432  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY    383,544     353,966  

Cellectis S.A.

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS (unaudited)

For the six-month period ended June 30, 2025

($ in thousands, except per share amounts)
 
    For the six-month period ended June 30,
    2024   2025
       
Revenues and other income        
Revenues   12,589     27,380  
Other income   3,412     2,842  
Total revenues and other income   16,002     30,222  
Operating expenses        
Research and development expenses   (45,841 )   (45,012 )
Selling, general and administrative expenses   (8,986 )   (9,780 )
Other operating income (expenses)   721     804  
Total operating expenses   (54,107 )   (53,988 )
         
Operating income (loss)   (38,105 )   (23,766 )
         
Financial gain (loss)   18,023     (18,098 )
         
Income tax    455     –   
         
Net income (loss)
 
  (19,627 )   (41,863 )
Attributable to shareholders of Cellectis   (19,627 )   (41,863 )
Basic net income (loss) attributable to shareholders of Cellectis, per share ($/share)   (0.24 )   (0.42 )
Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share)   (0.24 )   (0.42 )
         
Number of shares used for computing        
Basic   80,881,026     100,231,292  
Diluted   80,881,026     100,231,292  
         

UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS

For the three-month period ended June 30, 2025

($ in thousands, except per share amounts)
 
    For the three-month period ended June 30,
    2024   2025
       
Revenues and other income        
Revenues   8 061     16,725  
Other income   1,442     1,469  
Total revenues and other income   9,504     18,193  
Operating expenses        
Research and development expenses   (23,518 )   (23,080 )
Selling, general and administrative expenses   (3,882 )   (5,078 )
Other operating income (expenses)   686     378  
Total operating expenses   (26,714 )   (27,779 )
         
Operating income (loss)   (17,211 )   (9,586 )
         
Financial gain (loss)   (8,251 )   (14,150 )
         
Income tax   193      
         
Net income (loss)   (25,270 )   (23,736 )
Attributable to shareholders of Cellectis   (25,270 )   (23,736 )
Attributable to non-controlling interests        
Basic and diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share)   (0.28 )   (0.24 )
Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share)   (0.28 )   (0.24 )
         
Number of shares used for computing        
Basic   89,852,142     100,305,204  
Diluted   89,852,142     100,305,204  



Note Regarding Use of Non-IFRS Financial Measures

Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS.
Because adjusted net income (loss) attributable to shareholders of Cellectis excludes non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis.

RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited)

For the six-month period ended June 30, 2025

($ in thousands, except per share data)
 
    For the six-month period ended June 30,
    2024   2025
       
Net income (loss) attributable to shareholders of Cellectis   (19,627 )   (41,863 )
Adjustment:            
Non-cash stock-based compensation expense attributable to shareholders of Cellectis   1,717     2,258  
Adjusted net income (loss) attributable to shareholders of Cellectis   (17,910 )   (39,606 )
Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share)   (0.22 )   (0.40 )
         
Weighted average number of outstanding shares, basic (units)   80,881,026     100,231,29
2
 
         
Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share)   (
0.22
)   (0.40 )
         
Weighted average number of outstanding shares, diluted (units)   80,881,026     100,231,29
2
 

RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited)

For the three-month period ended June 30, 2025

($ in thousands, except per share data)
 
    For the three-month period ended June 30,
    2024   2025
       
Net income (loss) attributable to shareholders of Cellectis   (25,270 )   (23,736 )
Adjustment:            
Non-cash stock-based compensation expense attributable to shareholders of Cellectis   830     1,282  
Adjusted net income (loss) attributable to shareholders of Cellectis   (24,440 )   (22,454 )
Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share)   (0.27 )   (0.22 )
         
Weighted average number of outstanding shares, basic (units) (1)   89,852,142     100,305,204  
         
Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1)   (0.27 )   (0.22 )
         
Weighted average number of outstanding shares, diluted (units) (1)   89,852,142     100,305,204  



About Cellectis
 
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

TALEN® is a registered trademark owned by Cellectis.

Cautionary Statement 

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “will”, “in anticipation with”, “expect”, “potential”, “may,” “believe,” “foresee” or the negative of these and similar expressions. These forward-looking statements are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things the presentation of data for our BALLI-01 and NatHaLi-01 clinical trials, the timing and ability to progress our BALLI-01 into a pivotal Phase 2 trial, the progress of our R&D activities under our AstraZeneca partnership, the timing and outcome of our arbitration with Servier, and the sufficiency of cash, cash equivalent and fixed-term deposits to fund our operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to the sufficiency of cash, cash equivalent and fixed-term deposits to fund our operations, which we refer to as our runway, we note that our operating plans, including product development plans, may change as a result of various factors. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2024 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at www.sec.gov, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected]
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected]

________________________

1 Cash, cash equivalents and fixed-term deposits include restricted cash of $4.4 million as of June 30, 2025 and fixed-term deposits of $166.3 million as of June 30, 2025, of which $136.1 million are classified as current financial assets and $30.2 million are classified as non-current financial assets (due to a fixed bank deposit investment maturing in October 2026, including accrued interest).

Attachment



Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease

New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased specialty care, and meaningful reductions in hospitalizations (15% lower) and 30-day readmissions (18% lower).

WILMINGTON, Del., Aug. 04, 2025 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released a new whitepaper demonstrating how Counterpart Assistant (“CA”) technology supports improved management of COPD. The analysis, titled Driving Clinical Excellence in Chronic Disease: Counterpart Assistant’s Role in Chronic Obstructive Pulmonary Disease Care,” details strong correlations between CA-enabled primary care and better identification, management, and outcomes for COPD patients enrolled in Clover Health’s Medicare Advantage (MA) plans.

Key highlights of the study include:

  • Greater disease identification: New members with no prior COPD diagnosis who joined a Clover MA plan from another MA plan were 75% more likely to be diagnosed with COPD within their first year of joining Clover when under the care of a PCP that uses CA.
  • More frequent specialty care access: COPD patients attributed to a PCP that uses CA recorded an 18% higher average number of outpatient pulmonology visits.
  • Fewer inpatient hospitalizations: Relationships with PCPs live on CA were correlated with a 15% lower average number of all-cause hospitalizations and an 18% lower average number of 30-day readmissions.

“COPD remains one of the most burdensome chronic conditions that impacts seniors,” said Dr. David Tsay, MD PhD, Chief Medical Officer at Counterpart Health and co-author of the whitepaper. “By surfacing timely, patient-specific insights at the point of care, Counterpart Assistant empowers clinicians to detect and coordinate appropriate specialty care for COPD, ultimately keeping more patients out of the hospital.”

CA synthesizes 100+ real-time data streams with the latest evidence-based guidelines to present actionable recommendations inside a clinical workflow. Earlier analyses have demonstrated CA’s positive correlation with better patient care on Diabetes, Chronic Kidney Disease, Medication Adherence, and, most recently, Congestive Heart Failure. This COPD study extends that evidence base, underscoring CA’s ability to drive proactive, longitudinal management across high-risk chronic diseases.

“This whitepaper shows how translating raw data into real-time clinical insight can transform care,” said Conrad Wai, CEO of Counterpart Health. “By equipping physicians with timely, meaningful guidance, Counterpart Assistant helps deliver better outcomes for patients and reduce costs.” 

This whitepaper is Counterpart’s fifth retrospective data analysis measuring CA’s clinical impact on chronic disease management. Building on prior work in heart failure, diabetes, chronic kidney disease, and medication adherence, the new COPD findings further validate CA as a transformative platform for physician enablement and value-based care success.

To learn more about Counterpart Health, visit: www.counterparthealth.com

About Counterpart Health


Counterpart Health
, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes, Chronic Kidney Disease, and Congestive Heart Failure management, and Clinical Quality.

Investor Relations:

Ryan Schmidt
[email protected]

Press Inquiries:


[email protected]